How many insider trades does FilingIQ track for CMMB?

FilingIQ tracks 33 Form 4 insider transactions for CMMB (Chemomab Therapeutics Ltd.), covering filings from Mar 16, 2021 onwards. 4 of those were filed in the last 90 days.

Are CMMB insiders net buyers or net sellers?

Across the full Form 4 history for CMMB, 23 transactions (70%) were open-market purchases and 7 (21%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does CMMB insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is CMMB in?

Chemomab Therapeutics Ltd. (CMMB) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $14.40M.

CMMB insider trading

NasdaqCM Healthcare

Chemomab Therapeutics Ltd. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

70% / 21%

Market cap

$14.40M

About Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.

Company website: www.chemomab.com

CMMB insider activity at a glance

FilingIQ has scored 33 insider transactions for CMMB since Mar 16, 2021. The most recent filing in our index is dated May 29, 2026.

Across the full history, 23 open-market purchases and 7 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on CMMB insider trades is 61.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live CMMB trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,234

UNITED THERAPEUTICS Corp

APLS 277

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

GH 187

Guardant Health, Inc.

BMY 182

BRISTOL MYERS SQUIBB CO

HOLX 142

HOLOGIC INC

ADPT 140

Adaptive Biotechnologies Corp

KNSA 139

Kiniksa Pharmaceuticals International, plc

Frequently asked

How many insider trades does FilingIQ track for CMMB?: FilingIQ tracks 33 Form 4 insider transactions for CMMB (Chemomab Therapeutics Ltd.), covering filings from Mar 16, 2021 onwards. 4 of those were filed in the last 90 days.
Are CMMB insiders net buyers or net sellers?: Across the full Form 4 history for CMMB, 23 transactions (70%) were open-market purchases and 7 (21%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does CMMB insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is CMMB in?: Chemomab Therapeutics Ltd. (CMMB) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $14.40M.

Methodology & sources

Every CMMB insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.